1186193-95-2

Basic information

• Product Name: methyl 2,6-difluoro-3-(N-(propylsulfonyl)propylsulfonamido)benzoate
• Synonyms: methyl 2,6-difluoro-3-(N-(propylsulfonyl)propylsulfonamido)benzoate
• CAS NO: 1186193-95-2
• Molecular Weight: 399.437
• Mol File: 1186193-95-2.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: methyl 2,6-difluoro-3-(N-(propylsulfonyl)propylsulfonamido)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2,6-difluoro-3-(N-(propylsulfonyl)propylsulfonamido)benzoate(1186193-95-2)
• EPA Substance Registry System: methyl 2,6-difluoro-3-(N-(propylsulfonyl)propylsulfonamido)benzoate(1186193-95-2)

Safety Data

• Hazardous Substances Data: 1186193-95-2(Hazardous Substances Data)

Upstream product

• 13671-00-6 methyl 2,6-difluorobenzoate 
• 385-00-2 2,6-difluorobenzoic acid 
• 84832-01-9 methyl 2,6-difluoro-3-nitrobenzoate 
• 83141-10-0 2,6-difluoro-3-nitrobenzoic acid 
• 10147-36-1 n-propanesulfonyl chloride 
• 84832-02-0 methyl 3-amino-2,6-difluorobenzoate 

Downstream Products

• 1282461-33-9 2,6-difluoro-N-(2-phenyl-3H-imidazo[4,5-b]pyridin-6-yl)-3-(N-(propylsulfonyl)propylsulfonamido)benzamide 
• 1103234-56-5 2,6-difluoro-3-(propane-1-sulfonylamino)benzoic acid 
• 1103234-57-6 N-(3-amino-2,4-difluorophenyl)propane-1-sulfonamide 
• 1186193-96-3 2,6-difluoro-3-(N-(propylsulfonyl)(propylsulfonamido))benzoic acid 
• 1269421-68-2 4-chloro-N-(2,6-difluoro-3-(propylsulfonamido)phenyl)quinazoline-8-carboxamide 
• 1269420-21-4 4-amino-quinazoline-8-carboxylic acid [2,6-difluoro-3-(propane-1-sulfonylamino)phenyl]amide 
• 1269421-69-3 4-(bis(4-methoxybenzyl)amino)-N-(2,6-difluoro-3-(propylsulfonamido)phenyl)pyrido[4,3-d]pyrimidine-8-carboxamide 
• 1269420-22-5 4-amino-pyrido[4,3-d]pyrimidine-8-carboxylic acid [2,6-difluoro-3-(propane-1-sulfonylamino)-phenyl]-amide 
• 1269421-77-3 N-(3-amino-2,4-difluorophenyl)pyrrolidine-1-sulfonamide 
• 1269421-78-4 N-(2,6-difluoro-3-(pyrrolidine-1-sulfonamido)phenyl)-4-(2,4-dimethoxybenzylamino)quinazoline-8-carboxamide 
• 1269420-56-5 4-amino-quinazoline-8-carboxylic acid [2,6-difluoro-3-(pyrrolidine-1-sulfonylamino)-phenyl]-amide 
• 1269421-85-3 N-(2,6-difluoro-3-(propylsulfonamido)phenyl)-4-(2,4-dimethoxybenzyl-amino)-6-(3-hydroxyprop-1-ynyl)quinazoline-8-carboxamide 
• 1269420-62-3 4-amino-6-(3-hydroxy-prop-1-ynyl)-quinazoline-8-carboxylic acid [2,6-difluoro-3-(propane-1-sulfonyl-amino)phenyl]amide 
• 1269420-79-2 quinazoline-8-carboxylic acid [2,6-difluoro-3-(propane-1-sulfonylamino)-phenyl]-amide 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.

HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS

Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.